Navigation Links
Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Date:5/17/2012

SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL.

The update on data presented for the first time will specifically include: 1) safety and efficacy data from the phase II CLL single agent trial in treatment-naive patients; 2) safety and efficacy data from the phase Ib/II CLL combination trial with ofatumumab in relapsed or refractory patients and 3) safety and efficacy data from the phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory patients. Pharmacyclics plans to present a material update on the ibrutinib clinical development program in a press release after the ASCO oral presentations on Monday, June 4, 2012 and expects to hold a conference call as well on Wednesday, June 6, 2012 at 1:30 PM PT/4:30 PM ET.

Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
Location: E354a
Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
This Abstract was selected to be presented at the "Best of ASCO Meetings."

Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
Location: E354a
Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio. 

Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
Location: S405
Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.  Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
2. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
3. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
4. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
5. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
6. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
7. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
9. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
10. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
11. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)...  The China and Canada joint tech ... water, energy and detergent, and features a powerful disinfection process. ... washing machine that washes and sanitizes women,s panties or babies, cloth ... ... does not require an external water inlet. ...
(Date:5/10/2017)... Radiology has become the number one diagnostic ... spiraled to the number one ranking as a result.  ... before as the most complete and reliable method for ... back pain an MRI may confirm a suspected herniated ... in entirely different treatment protocols.  In these circumstances, patients ...
(Date:5/9/2017)... PORTLAND, Ore. , May 9, 2017 /PRNewswire/ ... company that provides technology solutions to improve the ... reported financial results for the first quarter ended ... that our products enable our customers to identify ... them to intervene before events like heart attacks ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... 2017 , ... Diagnotes, an Indianapolis-based digital healthcare communication company, ... secure clinical communication platform. The platform allows clinicians to easily escalate their preferred ... urgency of a situation. , “We know from our daily lives that ...
(Date:5/23/2017)... ... , ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications ... Connected Health and IoT: Technology Innovators and Disruption , the workshop is part of ... research and consulting firm specializing in emerging consumer technology products and services. , ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... now receive treatment using the SPEED System™ Orthodontics, with or without a referral, ... orthodontist in El Segundo, CA, who is skilled in providing patients with ...
(Date:5/23/2017)... ... May 23, 2017 , ... Patients in need of ... Angela Cotey’s practice to schedule an appointment, with or without a referral. Dr. Cotey ... pulpotomy treatments to pediatric patients as a healthy alternative to a tooth extraction. , ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
Breaking Medicine News(10 mins):